Psilocybin from ‘Magic Mushrooms’ Demonstrates Depression Relief in Cancer Patients: Study

Psilocybin, the active compound in “magic mushrooms,” traditionally associated with recreational drug use, is gaining recognition for its potential as a rapid-acting antidepressant. A study published in Cancer reveals its positive impact on individuals with cancer experiencing depression. Dr. Manish Agrawal, the study’s lead author and CEO of Sunstone Therapies, emphasized the need for holistic cancer care. In the trial, 30 participants with cancer and moderate-to-severe depression received a single 25-milligram dose of synthesized psilocybin along with therapist-led one-on-one and group sessions. The preparation and shared experience in small groups contributed to positive outcomes, with average depression scores dropping significantly eight weeks post-treatment. Side effects were mild, including nausea and headaches. A follow-up study highlighted the overwhelmingly positive views of participants, emphasizing the transformative impact and improved coping mechanisms. While promising, the authors stress the need for further research in larger patient groups and comparative studies before psilocybin is integrated into standard clinical practice.